Trial
NCT01424501
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Tuberculosis
Intervention
GSK Biologicals' investigational TB vaccine GSK 692342
Why stopped
Due to a safety signal found at a planned interim safety review, further conduct of this safety study is not recommended hence the study was terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-20